In the AT HOME-HF pilot trial (2024), the subcutaneous furosemide pump (FuroscixTM) was compared with conventional IV loop diuretics for decongestion in worsening HF outpatients (n = 34).7 Although the primary composite endpoint – a 30-day hierarchical win ratio of cardiovascular (CV) death, HF events and NT-proBNP change – was not statistically significant, subcutaneous administration achieved enhanced weight loss and improvements in dyspnea, New York Heart Association (NYHA) functional status, and Kansas City Cardiomyopathy Questionnaire (KCCQ) score (Table 1). Here, NPPB is linked to hydrops fetalis.